Showing results (411-420 of 474) with videos related to

Sort By:
Pageof 48
Journal for Immunotherapy of Cancer|July 24, 2026
Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trialMaria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, et al.
Annals of Surgical Oncology|May 18, 2024
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian CohortLisanne P Zijlker, Henry Chen, Andrew J Spillane, et al.
Genes|April 28, 2023
Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto RicoJulyann Perez-Mayoral, Maria Gonzalez-Pons, Hilmaris Centeno-Girona, et al.
Blood Advances|June 17, 2026
KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasmPaula Navarro-Navarro, Carlos Maria Fernandez Gimenez, Andrés C García-Montero, et al.
Cancer Research|August 5, 2008
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerKatherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, et al.
Stroke (Hoboken, N.J.)|January 26, 2026
Predicting Recanalization Failure With Conventional Devices During Endovascular Treatment Related to Vessel OcclusionAlan Flores, Marcos Elizalde, Laia Seró, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Access Microbiology|October 16, 2023
Monitoring and tracking the spread of SARS-CoV-2 in Asturias, SpainJose Maria Gonzalez-Alba, Susana Rojo-Alba, Zulema Perez-Martinez, et al.
Plos One|September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Pageof 48